Verve Therapeutics, Inc. (VERV)

6.41 0.00 (0.00%) 收市：04:00PM EDT

Verve Therapeutics, Inc.

201 Brookline Avenue
Suite 601
Cambridge, MA 02215
United States
617 603 0070
https://www.vervetx.com

版塊: Healthcare
行業: Biotechnology
全職員工: 255

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Sekar Kathiresan M.D.	Co-Founder, CEO & Director	973.25k	無	1973
Ms. Allison Dorval	CFO & Principal Accounting Officer	711.76k	無	1976
Dr. Andrew M. Bellinger M.D., Ph.D.	Chief Scientific Officer	758.29k	無	1978
Mr. Andrew D. Ashe J.D.	President, COO & General Counsel	703.85k	無	1967
Dr. Kiran Musunuru M.D., M.P.H., Ph.D.	Co-Founder	無	無	無
Dr. J. Keith Joung M.D., Ph.D.	Co-Founder	無	無	無
Dr. Anthony Philippakis M.D., Ph.D.	Co-Founder & Scientific Advisory Board Member	7.97k	無	無
Dr. Barry S. Ticho FACC, M.D., Ph.D.	Co-Founder	無	無	1961
Mr. Issi Rozen M.B.A.	Co-Founder & Strategic Advisor	無	無	無
Ms. Joan Nickerson M.B.A.	Chief Administrative Officer	無	無	1969

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

公司管治

截至 2024年5月1日 止，Verve Therapeutics, Inc. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中：8；董事會：7；股東權利：8；現金賠償：8。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。